Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Journal of Experimental Hematology ; (6): 33-38, 2019.
Article Dans Chinois | WPRIM | ID: wpr-774362

Résumé

OBJECTIVE@#To investigate the clinical features of acute myeloid leukemia patients aged over 80 years.@*METHODS@#The clinical data from 24 cases of acute myeloid leukemia (non-M3) aged over 80 years were analyzed retrospectively. Clinical characteristics, therapeutic efficacy and overall survival rate of the patients received low dose chemotherapy and/or decitabine were compared with that received only supportive care.@*RESULTS@#According to FAB classification, the 10 patients were M2 subtypes (41.7%), the 7 patients were M4 subtypes (29.2%), the 4 patiens were M5 (16.7%), the 3 patients were unclassifed (16.5%). 22 patients (91.0%) were complicated with underling diseases. Among 13 patients received low dose chemotherapy or decitabine, 8 cases (61.5%) achived partial remission or higher remission. The median survival time of patients who reseived chemotherapy was 30 weeks, and signicantly longer than that of patients received supportive care (median survival time was 9 weeks (P<0.05)). The univariated analysis showed that WBC≥50×10/L, ECOG≥2 and received supportive care were unfavonrable prognostic factors for overall survival.@*CONCLUSION@#More than half of patients aged over 80 years who received individudized treatment can achieve partial remission or higher remission, and can have more longer survival time..


Sujets)
Sujet âgé de 80 ans ou plus , Humains , Décitabine , Leucémie aigüe myéloïde , Études rétrospectives , Taux de survie , Résultat thérapeutique
SÉLECTION CITATIONS
Détails de la recherche